Croda announces the acquisition of Nautilus Biosciences Canada

| By | API, Biotechnologies

Croda International Plc, a British speciality chemicals company, announced that it has acquired Nautilus Biosciences Canada Inc, a technology-rich marine biotechnology company based in Charlottetown, Prince Edward Island, Canada.

Established in 1925, Croda produces and sells high performance ingredients in North America, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. Company has manufacturing sites and offices in 36 countries.

Nautilus was founded in 2007 and, together with its world class scientists, focuses on using marine microbial biodiversity to discover novel actives and materials. Through this acquisition and the associated patents, Croda will utilise this innovative science for applications across all its market sectors.

Croda and Nautilus already have a proven history of successful collaboration, having worked closely together for the past six years developing specific applications for skin care and hair care, as well as crop care. Croda intends to establish Nautilus as a Croda Centre of Innovation for Marine Biotechnology at Nautilus’ existing base at the University of Prince Edward Island. This location is ideal for biotechnology research and has already attracted and facilitated partnerships with many other biotechnology-based companies. Nautilus has exclusive global access to the Marine Microbial Library which is based at the University of Prince Edward Island.

Steve Foots, Chief Executive of Croda, said: “This is another clear example of how sustainable innovation is underpinning our growth plans. With Nautilus as part of the Croda Group, we further expand our expertise in biotechnology; the Nautilus team that will join us have extensive knowledge and expertise in marine biotechnology, also known as “blue biotechnology”. We will be able to bring new, patented products to market, alongside our already well-known green and white biotechnology ingredients, giving us the full spectrum of capabilities within this field of science.”

SOURCE: croda
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.